[Update of recommendations on the use of palivizumab as prophylaxis in RSV infections]. / Actualización de las recomendaciones de la Sociedad Española de Neonatología para la utilización del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial.
An Pediatr (Barc)
; 82(3): 199.e1-2, 2015 Mar.
Article
en Es
| MEDLINE
| ID: mdl-25453311
The Standards Committee of the Spanish Neonatology Society (SENeo) considers that the new document from the American Academy of Pediatrics, including recommendations for palivizumab use to prevent serious infections produced by the Respiratory Syncytial Virus (RSV), provides no new scientific evidence which would justify the modification of the current recommendations of the SENeo. However, some adjustments to the criteria of the existing recommendations are proposed to reduce the cost of the drug by its correct and judicious management.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Infecciones por Virus Sincitial Respiratorio
/
Palivizumab
Tipo de estudio:
Guideline
Límite:
Humans
/
Infant
Idioma:
Es
Revista:
An Pediatr (Barc)
Asunto de la revista:
PEDIATRIA
Año:
2015
Tipo del documento:
Article
Pais de publicación:
España